RxDoctor Payments DataLook up a doctor →

Angela Alistar, MD

Hematology & Oncology · Winston Salem, NCNPI 1831349745

Payments from drug & device makers

$1,519,151in general payments, 2019–2025

Across 1,161 payments — averaging $1308.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Products Limited$394K
  • Merck$284K
  • E.r. Squibb & Sons, L.L.C.$270K
  • Alkermes, Inc.$170K
  • Aadi Bioscience, Inc.$150K
  • AstraZeneca$109K
  • plus $143K from 54 others
$1,161in research payments, 2019–2025

Across 2 payments — averaging $580.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Roche Products Limited64$394,035
Merck156$283,747
E.r. Squibb & Sons, L.L.C.182$270,288
Alkermes, Inc.40$169,676
Aadi Bioscience, Inc.6$149,911
AstraZeneca(2 entities)118$108,820
Genentech, Inc.7$39,127
Amgen23$32,000
QED Therapeutics, Inc.10$13,570
Seagen Inc.33$11,193
Exelixis Inc.24$10,105
Array Biopharma Inc11$9,188
Pfizer40$5,758
Corcept Therapeutics10$5,319
Bristol Myers Squibb6$3,057
Takeda Pharmaceuticals U.S.A., Inc.7$2,855
Daiichi Sankyo Inc.106$2,439
Beone Medicines USA, Inc.1$1,950
Jazz Pharmaceuticals Inc.9$1,134
Novartis50$714
Eisai Inc.33$504
Johnson & Johnson(2 entities)24$399
GSK16$284
Mirati Therapeutics, Inc.19$281
Pharmaessentia USA Corporation14$230
Sanofi12$222
Incyte Corporation13$195
Lilly USA, LLC9$160
Astellas Pharma US Inc8$146
Regeneron Healthcare Solutions, Inc.9$141
Karyopharm Therapeutics Inc.8$125
Foundation Medicine, Inc.5$110
AbbVie8$110
Ipsen Biopharmaceuticals, Inc7$106
Genentech USA, Inc.7$104
Bayer6$102
Agios Pharmaceuticals, Inc.5$91
Taiho Oncology, Inc.5$80
Sirtex Medical Inc4$78
EMD Serono, Inc.4$65
F. Hoffmann-la Roche AG1$61
Boehringer Ingelheim4$58
Rigel Pharmaceuticals, Inc.3$57
Stemline Therapeutics Inc.3$52
Emmaus Medical, Inc.2$43
Genmab U.S., Inc.2$40
Puma Biotechnology, Inc.3$39
AVEO Pharmaceuticals, Inc.1$38
Cumberland Pharmaceuticals, Inc.2$36
Helsinn Therapeutics (U.S.), Inc.2$30
Pharmacyclics LLC, An Abbvie Company2$30
Pharmacosmos Therapeutics Inc.2$28
Dova Pharmaceuticals2$28
Acrotech Biopharma Inc.1$25
Blueprint Medicines Corporation1$17
Tersera Therapeutics LLC1$17
Morphosys, US Inc.1$17
Myriad Genetic Laboratories, Inc.1$16
Apellis Pharmaceuticals, Inc.1$16
Deciphera Pharmaceuticals Inc.1$15

How this compares

$1,519,151 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$98,362
Medicare patients
230
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Winston Salem

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →